Feed ATAI
AT

Atai Life Sciences N.V.

ATAI · NASDAQ

$7.35 +0.68% (+$0.05)
1M -0.41%
Market Cap $2.72B
P/E Ratio -
Div. Yield 91.84%
ROE 353.23%
Piotroski F-Score Moderate
5/9
Valuation
0 /100
Expensive
P/B 15.42x
P/S 607.91x
EV/EBITDA N/A
Growth
78 /100
Growing
Book val. growth 5.24%
Rev. growth 159.87%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 14,938.40%
Op. margin 3,274.31%
FCF margin 2,978.78%
Quality
0 /100
Poor
ROE 353.23%
ROA 252.35%
Asset turnover 0.02x
Debt
100 /100
Low
Current ratio 8.58x
Debt/Equity 0.02x
Net debt/EBITDA N/A
Stability
8 /100
Unstable
Rev. volatility 699.51%
EPS volatility 185.36%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ATAI
Online

O podjetju

Atai Life Sciences N.V. (ATAI) is a biotechnology company focused on research and development of novel therapeutic approaches in the field of mental health and psychiatric disorders. The company focuses on innovative therapies and drugs that have the potential to treat or improve the lives of people suffering from various mental illnesses, including depression, anxiety, post-traumatic stress disorder, addictions, and other disorders. Atai Life Sciences actively collaborates with other research institutions and biotechnology companies and invests in projects with the hope of discovering new treatment options. Their goal is to bring new drugs and therapies to the market that can make a significant difference for patients with mental disorders. Atai Life Sciences N.V. (ATAI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of mental health.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Srinivas G. Rao

Employees

99

Headquarters

New York

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

51d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.